Table 1.
Participant demographics
| All cohort n = 83 | Aβ elevated n = 20 | Aβ non-elevated n = 63 | p | |
| Age, y | 71.1±5.2 | 73.7±6.1 | 70.3±4.6 | 0.03 |
| Female, n (%) | 56 (67.5) | 14 (70.0) | 42 (66.7) | 0.78 |
| Education, y | 16.7±2.7 | 16.5±3.3 | 16.8±2.5 | 0.65 |
| BMI, kg/m2 | 26.7±4.0 | 26.1±4.1 | 26.8±4.0 | 0.53 |
| Systolic BP (mmHg) | 132.5±15.3 | 135.0±16.5 | 131.7±14.9 | 0.41 |
| Diastolic BP (mmHg) | 76.0±8.0 | 75.5±6.8 | 76.2±8.4 | 0.73 |
| Mean arterial BP (mmHg) | 73.8±11.6 | 73.1±10.3 | 74.0±12.0 | 0.69 |
| Total cholesterol (mmol/L) | 183.8±33.5 | 172.6±27.9 | 186.8±34.4 | 0.13 |
| Hypertension, n (%) | 31 (37.3) | 10 (50.0) | 21 (33.3) | 0.18 |
| Diabetes, n (%) | 3 (3.6) | 1 (5.0) | 2 (3.2) | 0.70 |
| CVD, n (%) | 5 (6.0) | 3 (15.0) | 2 (3.2) | 0.05 |
| Dyslipidemia, n (%) | 46 (55.4) | 10 (50.0) | 36 (57.1) | 0.58 |
| Smoking, n (%) | 2 (2.4) | 0 (0) | 2 (3.2) | 0.42 |
| ACE inhibitors, n (%) | 6 (7.2) | 2 (10.0) | 4 (6.3) | 0.58 |
| Calcium channel blocker, n (%) | 10 (12.0) | 3 (15.0) | 7 (11.1) | 0.64 |
| Beta blockers, n (%) | 12 (14.5) | 5 (25.0) | 7 (11.1) | 0.12 |
| Angiotensin II antagonist, n (%) | 10 (12.0) | 3 (15.0) | 7 (11.1) | 0.64 |
| Alpha adrenergic blocking, n (%) | 2 (2.4) | 0 (0) | 2 (3.2) | 0.42 |
| Antihyperlipidemic, n (%) | 39 (47.0) | 12 (60.0) | 27 (42.9) | 0.18 |
| Sex hormones, n (%) | 14 (16.9) | 1 (5.0) | 13 (20.6) | 0.10 |
| Thyroid, n (%) | 21 (25.3) | 8 (40.0) | 13 (20.6) | 0.08 |
| Bronchodialator, n (%) | 5 (6.0) | 1 (5.0) | 4 (6.3) | 0.83 |
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; ACE, angiotension converting enzyme.